cmpbsdb@gitpyr.UUCP (Don Barry) (11/20/85)
We read almost daily of the great advances being made in treatment of
leukemia, other sarcoma, hormone-dependent carcinoma, etc, but what of
the hard-to-treat carcinoma of the viscera, such as the kidneys, colon,
liver, etc? These carcinoma appear uniformly radiation-resistant, rather
impervious to chemotherapy, and all too metastatic.
I suspect one of the best avenues being researched at present are the
monoclonal antibodies with toxic attachments. Is there current work
being done on visceral carcinoma? Is any at the experimental or field
stage? I'm particularly interested on current work with hypernephroma,
and would appreciate the pooled knowledge of the net.
--
Don Barry (Chemistry Dept) CSnet: cmpbsdb%gitpyr.GTNET@gatech.CSNET
Georgia Institute of Technology BITNET: CMPBSDB @ GITVM1
Atlanta, GA 30332 ARPA: cmpbsdb%gitpyr.GTNET%gatech.CSNET@csnet-relay.ARPA
UUCP: ...!{akgua,allegra,amd,hplabs,ihnp4,seismo,ut-ngp}!gatech!gitpyr!cmpbsdbhsf@hlexa.UUCP (Henry Friedman) (11/20/85)
> I suspect one of the best avenues being researched at present are the > monoclonal antibodies with toxic attachments. Is there current work > being done on visceral carcinoma? Is any at the experimental or field > stage? I'm particularly interested on current work with hypernephroma, > and would appreciate the pooled knowledge of the net. .... > Don Barry (Chemistry Dept) CSnet: cmpbsdb%gitpyr.GTNET@gatech.CSNET I'm not familiar with hypernephroma, but the most promising research for the class of tumors you mention (other than the monoclonal antibody approach) involves the genetic-engineered version of the natural hormone TNF (tumor necrosis factor). Human testing has recently begun in the US (original live testing was in Japan). I believe four different genetic engineering companies are involved. A combination of TNF and interferon also showed promise. The first phases of live testing usually concentrate on issues of safety, but I'd think that some announcements of effectiveness will be due shortly. My sources are articles in the Wall Street Journal over the past few months (some of the best-documented popular medical reporting). --Henry Friedman
jcp@osiris.UUCP (Jody Patilla) (11/22/85)
> We read almost daily of the great advances being made in treatment of > leukemia, other sarcoma, hormone-dependent carcinoma, etc, but what of > the hard-to-treat carcinoma of the viscera, such as the kidneys, colon, > liver, etc? These carcinoma appear uniformly radiation-resistant, rather > impervious to chemotherapy, and all too metastatic. > A method for successful treatment of liver cancer was recently announced here at Hopkins. I believe it involves injections of drugs directly into the organ, which shrink it enough that it become operable or goes away altogether. Not all liver cancer patients are good candidates for this, but it does seem to be a major breakthrough for what was a previously lost cause. -- jcpatilla Mountain View is paid a diplomatic visit by giant Lunar reptiles that want our hot tubs but can't find any so they leave.